Quantbot Technologies LP Sells 1,789 Shares of Medpace Holdings, Inc. $MEDP

Key Points

• Quantbot Technologies LP significantly reduced its holdings in Medpace Holdings, Inc. by 41.3% during the first quarter, now owning only 2,539 shares worth approximately $774,000.
• Insider sales include Vice President Susan E. Burwig selling 7,500 shares for over $3.3 million, while General Counsel Stephen P. Ewald sold 3,000 shares for $1.35 million, resulting in notable decreases in their respective ownerships.
• Medpace stock is currently valued at $463.64, with a market cap of $13.02 billion, and recently reported quarterly earnings that exceeded analyst expectations.

Quantbot Technologies LP cut its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 41.3% during the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 2,539 shares of the company's stock after selling 1,789 shares during the period. Quantbot Technologies LP's holdings in Medpace were worth $774,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Brooklyn Investment Group grew its position in Medpace by 244.8% during the first quarter. Brooklyn Investment Group now owns 100 shares of the company's stock valued at $30,000 after purchasing an additional 71 shares in the last quarter. Whittier Trust Co. lifted its stake in Medpace by 47.3% in the first quarter. Whittier Trust Co. now owns 109 shares of the company's stock valued at $33,000 after acquiring an additional 35 shares during the last quarter. Colonial Trust Co SC lifted its stake in Medpace by 150.0% in the fourth quarter. Colonial Trust Co SC now owns 175 shares of the company's stock valued at $58,000 after acquiring an additional 105 shares during the last quarter. Bank Julius Baer & Co. Ltd Zurich acquired a new stake in Medpace in the first quarter valued at approximately $60,000. Finally, Assetmark Inc. lifted its stake in Medpace by 24.9% in the first quarter. Assetmark Inc. now owns 216 shares of the company's stock valued at $66,000 after acquiring an additional 43 shares during the last quarter. 77.98% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts have issued reports on MEDP shares. Truist Financial lifted their target price on shares of Medpace from $298.00 to $436.00 and gave the company a "hold" rating in a research note on Wednesday, July 23rd. Robert W. Baird lifted their target price on shares of Medpace from $313.00 to $490.00 and gave the company a "neutral" rating in a research note on Wednesday, July 23rd. UBS Group cut shares of Medpace from a "neutral" rating to a "sell" rating and lifted their target price for the company from $300.00 to $305.00 in a research note on Tuesday, July 29th. Barclays lifted their target price on shares of Medpace from $300.00 to $450.00 and gave the company an "equal weight" rating in a research note on Wednesday, July 23rd. Finally, William Blair reaffirmed a "market perform" rating on shares of Medpace in a report on Wednesday, July 23rd. Two research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat, Medpace has a consensus rating of "Reduce" and an average target price of $406.60.

Medpace Trading Down 0.1%

NASDAQ:MEDP traded down $0.54 during trading hours on Thursday, hitting $472.94. 202,838 shares of the company traded hands, compared to its average volume of 448,900. The stock has a market capitalization of $13.29 billion, a price-to-earnings ratio of 35.16, a P/E/G ratio of 2.95 and a beta of 1.42. Medpace Holdings, Inc. has a twelve month low of $250.05 and a twelve month high of $501.30. The firm has a 50-day moving average of $389.02 and a 200 day moving average of $337.53.

Medpace (NASDAQ:MEDP - Get Free Report) last released its earnings results on Monday, July 21st. The company reported $3.10 EPS for the quarter, beating the consensus estimate of $3.00 by $0.10. The firm had revenue of $603.31 million during the quarter, compared to analysts' expectations of $537.70 million. Medpace had a net margin of 18.74% and a return on equity of 67.66%. The business's quarterly revenue was up 14.2% compared to the same quarter last year. During the same period in the prior year, the company earned $2.75 EPS. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. Equities research analysts predict that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Insider Activity

In other Medpace news, CFO Kevin M. Brady sold 12,000 shares of the business's stock in a transaction on Thursday, July 24th. The shares were sold at an average price of $454.23, for a total value of $5,450,760.00. Following the sale, the chief financial officer owned 6,000 shares of the company's stock, valued at $2,725,380. The trade was a 66.67% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO August J. Troendle sold 48,487 shares of the business's stock in a transaction on Monday, July 28th. The shares were sold at an average price of $451.69, for a total transaction of $21,901,093.03. Following the completion of the sale, the chief executive officer directly owned 962,615 shares in the company, valued at $434,803,569.35. This trade represents a 4.80% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 115,070 shares of company stock worth $52,085,751. Corporate insiders own 20.30% of the company's stock.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.